LXRX News and Press, Lexicon Pharmaceuticals Inc. From 01/01/24

2024-01-01 01:27:26 ET Summary Lexicon Pharmaceuticals faces a critical phase with FDA-approved Inpefa, competing against established drugs like Jardiance. Financially stable short-term, Lexicon grapples with high marketing costs and rapid cash burn, raising long-term sustainabili...

2023-12-29 17:51:44 ET More on Lexicon Pharmaceuticals Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2023 Earnings Call Transcript Looking Back In On Lexicon Pharmaceuticals Lexicon to present data on cost-effectiveness of Inpefa on Tuesday Express Scripts to list ...

2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...

THE WOODLANDS, Texas, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 42nd Annual JPMorgan Healthcare Conference taking place January 8 – January 12, 2024. Lonnel Coats, Lexicon’s chief executive offic...

The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain in more than 20 years LX9211 has previously received Fast Track designation from t...

THE WOODLANDS, Texas, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2023: 35 th Annual Piper Sandler Healthcare Conference 6 th A...

Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately in MACE related outcomes as early as approximately three months in patients at high ...

THE WOODLANDS, Texas, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Healthcare Conference taking place November 14-16, 2023. Jeff Wade, Lexicon’s president and chief financial officer, and ...

2023-11-08 11:01:04 ET Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2023 Earnings Conference Call November 8, 2023, 08:00 AM ET Company Participants Carrie Siragusa - VP of Marketing Lonnel Coats - CEO Tom Garner - Chief Commercial Officer Craig Granowitz - Chief ...

2023-11-08 07:08:47 ET More on Lexicon Pharmaceuticals Looking Back In On Lexicon Pharmaceuticals Lexicon Pharmaceuticals Underway With Inpefa, But A Lot Of Hard Work Lexicon Rolls Out Inpefa For Heart Failure Amid Robust Competition Lexicon to present data o...